Clinical Trial Update: Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy

View source ↗

Summary

An update on a terminated clinical trial evaluating genetic factors in natalizumab-treated patients with progressive multifocal leukoencephalopathy (PML).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multifocal Leukoencephalopathy

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

Sponsor: Biogen | Conditions: Progressive Multifocal Leukoencephalopathy | Status: TERMINATED